Loading organizations...
§ Private Profile · San Diego, CA, USA
Clinical-stage biotechnology company developing oncology therapeutics for cancer patients, focused on CDK2 inhibitors.
Avenzo Therapeutics is a clinical-stage biotechnology company developing targeted oncology therapeutics for cancer patients, based in San Diego, California. Rather than conducting in-house discovery, the pre-revenue firm pursues a strategic licensing model to acquire and advance clinical-stage compounds, such as its lead candidate AVZO-021, a highly selective CDK2 inhibitor designed to treat advanced solid tumors. The enterprise successfully acquired the global rights to this primary clinical asset from Allorion Therapeutics in early 2024 to address oncology conditions including metastatic breast cancer. The organization operates with a team of 15 employees and has raised $347 million in total Series A venture capital equity financing, following an oversubscribed extension round, from lead investors including OrbiMed, Foresite Capital, SR One, and New Enterprise Associates. Avenzo Therapeutics was officially founded in 2022 by co-founders Athena Countouriotis and Mohammad Hirmand.
Avenzo Therapeutics has raised $406.5M across 3 funding rounds.
Avenzo Therapeutics has raised $406.5M in total across 3 funding rounds.
Avenzo Therapeutics has raised $406.5M across 3 funding rounds. Most recently, it raised $60.0M Series B in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 22, 2025 | $60M Series B | OrbiMed, SR ONE | Foresite Capital, Lilly Asia Ventures, Deep Track Capital, Delos Capital, INCE Capital, Longwood Fund, NEW Enterprise Associates, Quan Capital, Sands Capital, Sofinnova Investments, Surveyor Capital, TF Capital | Announced |
| Mar 26, 2024 | $150M Series A | Jakob Dupont, Deep Track Capital, NEW Enterprise Associates, Sands Capital | Foresite Capital, Judith LI, Carl Gordon, Delos Capital, INCE Capital, Quan Capital, TF Capital | Announced |
| May 25, 2023 | $196.5M Venture Round | — | — | Announced |
Avenzo Therapeutics has raised $406.5M in total across 3 funding rounds.
Avenzo Therapeutics's investors include OrbiMed, SR One, Foresite Capital, Lilly Asia Ventures, Deep Track Capital, Delos Capital, INCE Capital, Longwood Fund, New Enterprise Associates, Quan Capital, Sands Capital, Sofinnova Ventures.